Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 14 01 2019
accepted: 22 07 2019
entrez: 13 8 2019
pubmed: 14 8 2019
medline: 10 3 2020
Statut: epublish

Résumé

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis. Currently, early treatment is the only way to prevent further progression, as the pathogenesis of MRONJ has not yet been elucidated, and a standard treatment has not been established. The aim of this study was to identify a marker for early detection marker of MRONJ by exploring substances in saliva specific to MRONJ at an early stage. We collected salivary samples from 17 patients with MRONJ and conducted metabolomic analyses using capillary electrophoresis mass spectrometry for non-targeted analysis of hydrophilic metabolites. In the screening cohort, we compared the saliva of patients with stage ≥1 advanced MRONJ (n = 9) with that of controls without MRONJ before chemotherapy (n = 9). The top 5 most elevated salivary metabolites were histamine, 3-(4-hydroxyphenyl)propionate, malonate, carnosine, and hypotaurine. In the validation cohort, we analyzed additional patients with stage ≥1 advanced MRONJ (n = 8) and controls without MRONJ after chemotherapy (n = 9), confirming a significant 2.28-fold elevation in the salivary concentration of hypotaurine. These results revealed elevated salivary hypotaurine concentration as a potential marker for the early detection of MRONJ.

Identifiants

pubmed: 31404085
doi: 10.1371/journal.pone.0220712
pii: PONE-D-19-01225
pmc: PMC6690531
doi:

Substances chimiques

Biomarkers 0
Taurine 1EQV5MLY3D
hypotaurine 5L08GE4332

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0220712

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Acta Biol Hung. 2003;54(1):27-34
pubmed: 12705319
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
J Oral Maxillofac Surg. 2004 May;62(5):527-34
pubmed: 15122554
Clin Cancer Res. 2004 Dec 15;10(24):8442-50
pubmed: 15623624
J Clin Periodontol. 2005 Nov;32(11):1123-8
pubmed: 16212571
J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75
pubmed: 16243172
J Biol Chem. 2006 Jun 16;281(24):16768-76
pubmed: 16608839
Biochim Biophys Acta. 1991 Jan 23;1073(1):91-7
pubmed: 1846756
J Bone Miner Res. 2008 Jun;23(6):826-36
pubmed: 18558816
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12
pubmed: 19371809
J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72
pubmed: 19531404
Metabolomics. 2010 Mar;6(1):78-95
pubmed: 20300169
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):509-16
pubmed: 20674404
Am J Med. 2010 Nov;123(11):1060-4
pubmed: 20851366
J Bone Miner Res. 2011 Aug;26(8):1871-82
pubmed: 21351151
Nutr Rev. 2011 May;69(5):245-58
pubmed: 21521227
Oral Dis. 2012 Sep;18(6):621-3
pubmed: 22353421
Physiol Rev. 2013 Oct;93(4):1803-45
pubmed: 24137022
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Feb;117(2):204-13
pubmed: 24332520
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Appl Physiol Nutr Metab. 2014 Oct;39(10):1120-6
pubmed: 24988119
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
Int J Oral Maxillofac Surg. 2015 May;44(5):568-85
pubmed: 25726090
Placenta. 2015 Jun;36(6):693-8
pubmed: 25801460
J Bone Miner Res. 2015 Jun;30(6):1113-5
pubmed: 25988662
Clin Exp Immunol. 2015 Nov;182(2):149-53
pubmed: 26201380
FEBS Lett. 2016 Jan;590(1):22-33
pubmed: 26787461
Mass Spectrom (Tokyo). 2016;5(1):A0047
pubmed: 27446770
Sci Rep. 2016 Aug 19;6:31520
pubmed: 27539254
Amino Acids. 2017 Apr;49(4):761-770
pubmed: 28101653
Oncol Rep. 2017 May;37(5):2727-2734
pubmed: 28393236
Biochem J. 1988 Nov 15;256(1):251-5
pubmed: 2851980
Intern Med. 2018 Nov 15;57(22):3341
pubmed: 29984762
Sci Rep. 2018 Aug 13;8(1):12075
pubmed: 30104641
Clin Chim Acta. 2019 Feb;489:41-48
pubmed: 30481500

Auteurs

Wakako Yatsuoka (W)

Dental Division, National Cancer Center Hospital, Tsukiji, Chuo-ku, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.

Takao Ueno (T)

Dental Division, National Cancer Center Hospital, Tsukiji, Chuo-ku, Japan.

Kanako Miyano (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Japan.

Yasuhito Uezono (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Japan.
Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Japan.
Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tsukiji, Chuo-ku, Japan.

Ayame Enomoto (A)

Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan.

Miku Kaneko (M)

Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan.

Sana Ota (S)

Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan.

Tomoyoshi Soga (T)

Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan.

Masahiro Sugimoto (M)

Institute for Advanced Biosciences, Keio University, Tsuruoka City, Yamagata, Japan.
Research and Development Center for Minimally Invasive Therapies Health Promotion and Preemptive Medicine, Tokyo Medical University, Shinjuku, Japan.

Toshikazu Ushijima (T)

Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.
Division of Epigenomics, National Cancer Center Research Institute, Tsukiji, Chuo-ku, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH